Prostate Cell News Volume 7.15 | Apr 29 2016

Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression
Researchers investigated the expression of nuclear receptor corepressor 1 (NCOR1) in human prostate and prostate cancer and the role of NCOR1 in response to antiandrogens. [Clin Cancer Res] Abstract | Full Article

Specific Delivery of miRNA for High Efficient Inhibition of Prostate Cancer by RNA Nanotechnology
The authors report the application of RNA nanotechnology for specific and efficient delivery of anti-miRNA seed-targeting sequence to block the growth of prostate cancer in mouse models. [Mol Ther] Abstract

Long Non-Coding RNAs Harboring miRNA Seed Regions Are Enriched in Prostate Cancer Exosomes
Scientists characterized the expression of long non-coding RNAs (lncRNAs) in several prostate cancer exosomes and their parental cell lines. They showed that certain lncRNAs are enriched in cancer exosomes with the overall expression signatures varying across cell lines. [Sci Rep] Full Article

Detection of DNA Viruses in Prostate Cancer
Researchers tested prostatic secretions from men with and without prostate cancer (13 cases and 13 matched controls) or prostatitis (18 cases and 18 matched controls) with metagenomic sequencing. [Sci Rep] Full Article

Expression of Two WFDC1/ps20 Isoforms in Prostate Stromal Cells Induces Paracrine Apoptosis through Regulation of PTGS2/COX-2
Prostrate stromal 20 expression enhanced the proliferation of LNCaP cells, whereas stromal WPMY-1 cells were inhibited and underwent increased apoptosis. Prostrate stromal 20-expressing WPMY-1 cells secrete a potently proapoptotic conditioned media. [Br J Cancer] Abstract

Mitochondrial Dysfunction-Mediated Apoptosis Resistance Associates with Defective Heat Shock Protein Response in African-American Men with Prostate Cancer
Glycolytic pathway inhibitor dichloroacetate inhibited cell proliferation in both African–American (AA) prostate cancer (PCa) cells and Caucasian American (CA) PCa cells. AA cells possess reduced endogenous reactive oxygen species, mitochondrial membrane potential, and mitochondrial mass compared with CA cells. [Br J Cancer] Abstract

Tbx18 Regulates the Differentiation of Periductal Smooth Muscle Stroma and the Maintenance of Epithelial Integrity in the Prostate
The authors demonstrated for the first time that T-box transcription factor Tbx18 is required for the normal development of periductal smooth muscle stromal cells in prostate, particularly in the anterior lobe, with a clear impact on prostate health in adult mice. [PLoS One] Full Article

CLINICAL RESEARCH

Radium-223 Outcomes after Multiple Lines of Metastatic Castration-Resistant Prostate Cancer Therapy in Clinical Practice: Implication of Pre-Treatment Spinal Epidural Disease
Researchers investigated the impact of baseline spinal epidural disease on metastatic castration-resistant prostate cancer patients treated with radium-223. [Prostate Cancer Prostatic Dis] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Sophiris Bio to Present at Bloom Burton & Co. Healthcare Investor Conference
Sophiris Bio Inc. announced that Randall E. Woods, president and chief executive officer, will present a corporate overview and review recent clinical data. [Press release from Sophiris Bio Inc. discussing research to be presented at the 2016 Bloom Burton & Co. Healthcare Investor Conference, Toronto] Press Release

GenomeDx’s Decipher GRID and Decipher Tests to be Featured in Multiple Abstracts
GenomeDx Biosciences announced that eight abstracts featuring Decipher Genomics Resource Information Database (Decipher GRID^®) and Decipher^® Tests in Prostate and Bladder Cancer will be presented. [Press release from GenomeDx Biosciences discussing research to be presented at the 111^th American Urological Association (AUA) 2016 Annual Meeting, San Diego] Press Release

From our sponsor: Induce neural progenitor cells faster and more effectively. Watch the technical video.

Transition Therapeutics Announces Dosing of First Patient in Phase II Study of Drug Candidate TT701
Transition Therapeutics Inc. announced the dosing of the first patient of a Phase II study of selective androgen receptor modulator drug candidate TT701. The Phase II study will evaluate the efficacy and safety of TT701 in improving the symptoms of androgen deficiency in men with prostate cancer who have undergone radical prostatectomy for organ-localized prostate cancer. [Transition Therapeutics Inc.] Press Release

Aeterna Zentaris Acquires Exclusive U.S. Promotional Rights for APIFINY^® Prostate Cancer Blood Test
Aeterna Zentaris Inc. announced that it has acquired the exclusive right to promote APIFINY^®, the only cancer specific, non-PSA blood test to assess the risk for the presence of prostate cancer, throughout the entire United States pursuant to a new co-marketing agreement with Armune BioScience, Inc. [Aeterna Zentaris Inc.] Press Release

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the prostate cell community.

Research Technologist – Mammary and Prostate Stem Cell Biology (STEMCELL Technologies Inc.)

Postdoctoral Research Fellow – Molecular Epidemiology of Cancer (Fred Hutchinson Cancer Research Center)

PhD Studentship – Cancer Metabolism (German Cancer Research Center)

Postdoctoral Fellow – Genetic Determinants of Cancer (Memorial Sloan-Kettering Cancer Center)

Postdoctoral Fellow – Prostate Cancer (Cleveland Clinic)

Postdoctoral Fellow – Prostate Epithelial Homeostasis and Carcinogenesis (Baylor College of Medicine)

Lead Scientist – Prostate Cancer (Memorial Sloan Kettering Cancer Center)

Postdoctoral Fellowship – Castration Resistant Prostate Cancer (University of Florida)

PhD Studentship – Wnt Signaling in Stem Cells and Cancer (German Cancer Research Center)

Research Group Leader – Stress Regulated Processes During Oncogenesis (INSERM)

Postdoctoral Research Fellow – Cell Cycle Control and Tumorigenesis (Fred Hutchinson Cancer Research Center)

Division Head – Medical Oncology (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.